Piperacillin(T-1220),a new semisynthetic penicillin-2-In vitro antimicrobial activity and synergy comparison with carbenicillin and getamicin

DOI Web Site PubMed
  • JONES R. N.
    Clinical Microbiology Laboratory, Kaiser Foundation Hospital Laboratories, Clackamas
  • PACKER R. R.
    Clinical Microbiology Laboratory, Kaiser Foundation Hospital Laboratories, Clackamas
  • BARRY A. L.
    Clinical Microbiology Laboratory, University of California( Davis)
  • BADAL R. E.
    Clinical Microbiology Laboratory, University of California( Davis)
  • THORNSBERRY C.
    Antimicrobics Investigation Section, Center for Disease Control
  • BAKER C.
    Antimicrobics Investigation Section, Center for Disease Control

書誌事項

タイトル別名
  • Piperacillin (T-1220), a new semisynthetic penicillin. II. In vitro antimicrobial activity and synergy comparison with carbenicillin and gentamicin.
  • Piperacillin T 1220 a new semisynthetic
  • <i>IN VITRO</i> ANTIMICROBIAL ACTIVITY AND SYNERGY COMPARISON WITH CARBENICILLIN AND GENTAMICIN

この論文をさがす

抄録

Piperacillin, a new semisynthetic penicillin, was found to have potent antimicrobial activity against nearly all (405) tested bacterial species. Piperacillin was consistently 4-16-fold more active than carbenicillin against the Enterobacteriaceae, 16-32-fold against Pseudomonas acruginosa and Pseudomonas species, and 16-fold against Streptococcus faecalis. Carbenicillin and piperacillin were equally effective against Staphylococcus aureus, but inactivated by beta-lactamase. A 38% overall synergy rate for the piperacillin-gentamicin combination was identified, a finding similar to that for carbenicillin-gentamicin. Highest incidences of synergy were found for both antibiotic pairs tested on gentamicin-resistant isolates (Ps. aeruginosa and Providencia). In vitro findings suggest that piperacillin alone or in combination with aminoglycosides may be highly efficacious in the treatment of most serious bacterial infections.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ